The application of Oncotype DX 21-gene assay in early-stage ER positive breast cancer

章　颖; 柳光宇

doi:10.19401/j.cnki.1007-3639.2017.08.012

您当前的位置：

首页 >

文章列表页 >

The application of Oncotype DX 21-gene assay in early-stage ER positive breast cancer

更新时间：2025-12-31

- The application of Oncotype DX 21-gene assay in early-stage ER positive breast cancer
- China Oncology Vol. 27, Issue 8, Pages: 675-680(2017)
- 作者机构：
  
  复旦大学附属肿瘤医院乳腺外科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2017.08.012
  CLC：
- Published Online：21 September 2017，
  
  Published：21 September 2017
- 稿件说明：
移动端阅览
章　颖,柳光宇. Oncotype DX 21基因检测在ER阳性早期乳腺癌中的应用[J]. 中国癌症杂志, 2017, 27(8): 675-680.

章　颖, 柳光宇. The application of Oncotype DX 21-gene assay in early-stage ER positive breast cancer[J]. China Oncology, 2017, 27(8): 675-680.
章　颖,柳光宇. Oncotype DX 21基因检测在ER阳性早期乳腺癌中的应用[J]. 中国癌症杂志, 2017, 27(8): 675-680. DOI： 10.19401/j.cnki.1007-3639.2017.08.012.

章　颖, 柳光宇. The application of Oncotype DX 21-gene assay in early-stage ER positive breast cancer[J]. China Oncology, 2017, 27(8): 675-680. DOI： 10.19401/j.cnki.1007-3639.2017.08.012.

摘要

在诸多评估雌激素受体(estrogen receptor，ER)阳性早期乳腺癌复发风险的多基因工具中，Oncotype DX 21基因检测因其独特的疗效预测作用而被广泛应用于淋巴结阴性患者。多项回顾性研究已证明其在淋巴结阳性人群同样具有预后预测价值，但前瞻性临床试验证据仍不充分。该检测能协同其他重要临床病理因素，影响乳腺癌患者的辅助治疗方案，且具较高的成本效益。该研究就21基因检测对早期乳腺癌患者的预后预测价值、独特优势、辅助治疗决策影响、成本效果和现存争议进行综述。

Abstract

Several multi-gene assays have been developed to predict the risk of recurrence in patients with early-stage

estrogen receptor (ER) positive breast cancer. Among them

Oncotype DX 21-gene assay is widely applied among node-negative patients because of its unique prediction of therapeutic benefit. Although many retrospective studies have proved its prognostic and predictive value in node-positive population

evidence from large prospective clinical trials remains insufficient. When combined with clinicopathological variables

the assay has been shown to impact adjuvant treatment decision making in a cost-effective manner. This article reviewed the available clinical evidence for the prognostic and predictive value

unique advantages

the effect on treatment decision making

cost-effectiveness and contradictories of 21-gene assay in early-stage luminal breast cancer patients.

关键词

Keywords

references

Views

3594

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effectiveness and safety analysis of camrelizumab combined with chemotherapy and targeted therapy in patients with recurrent, metastatic, and treatment-naive advanced cervical cancer: a retrospective cohort study

Research on the association of breast cancer patients’ prognosis with internal mammary sentinel lymph node biopsy

Receptor discordance between primary breast cancer and liver metastases

Response rate and clinical outcome of HER2-low breast cancer after neoadjuvant therapy: a single-center retrospective study

Internal mammary sentinel lymph node biopsy for breast cancer: a long-term follow-up research for assessment of prognosis and guiding individualized internal mammary lymph node irradiation

Related Author

Sumei FAN

Congling XIN

Laifang ZHU

Chang LIU

Rui XU

Zhengrong ZHOU

Xi CHENG

Ruijie JIA

Related Institution

Department of Surgical Oncology, Minhang Branch, Fudan University Shanghai Cancer Center

Department of Pharmacy, Minhang Branch, Fudan University Shanghai Cancer Center

Department of Diagnostic Radiology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Diagnostic Radiology, Minhang Branch, Fudan University Shanghai Cancer Center

Department of Gynecological Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

AI问答

⁰